<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335323">
  <stage>Registered</stage>
  <submitdate>13/04/2010</submitdate>
  <approvaldate>23/04/2010</approvaldate>
  <actrnumber>ACTRN12610000328077</actrnumber>
  <trial_identification>
    <studytitle>Orally inhaled heparin in patients with cystic fibrosis (CF)</studytitle>
    <scientifictitle>A phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin inhalation in patients with cystic fibrosis (CF)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ISRCTN78613729 issued by International Standard Randomized Controlled Trial Number Register.</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary symptoms of cystic fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomised to receive one of three daily dose levels of heparin treatment or matching placebo; to be self-administered by inhalation by the patient twice daily for four consecutive weeks. Nominal Daily Doses to be studied are: 11400 International Units (IU), 22800 IU and 45600 IU. 

For each patient there will be a screening period of 4 weeks, a treatment period of 4 weeks with a follow-up period of 2 weeks.</interventions>
    <comparator>Excipient based placebo self-administered by inhalation</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability assessed by treatment-emergent adverse events, laboratory data (including haematology, clinical chemistry and urinalysis); physical examination; vital signs including blood pressure, heart rate, respiratory rate, temperature and weight; concomitant medication.</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of Sputum properties (i.e., rheological viscoelasticity/physicochemical measurement parameters)</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of Sputum inflammatory markers</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Measurement of pH of exhaled breath condensate</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of  Blood plasma inflammatory markers</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of blood coagulation through Activated Partial Thromboplastin Time and platelet count</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of  Visual Analogue Scale (VAS) parameters including cough; breathlessness; general wellbeing.</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of  Sputum microbiology</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of  Pulmonary function parameters by spirometry including forced expiratory volume in one second (FEV1) and forced vital capacity (FVC)</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of Response to the Cystic Fibrosis Questionnaire</outcome>
      <timepoint>Five visits to the trial centre are included: screening, baseline, week 2, week 4 and, for follow-up, week 6.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Male or female, aged 16 years or older 
2. Non-smoker 
3. Written informed consent obtained prior to any trial specific procedures 
4. Confirmed diagnosis of CF lung disease (i.e., respiratory clinical symptoms and positive sweat test or disease inducing mutations) by CF expert/investigator 
5. Forced expiratory volume in one second (FEV1) at 40 - 90% of predicted value for age, sex and height at screening and baseline 
6. FEV1 value at Baseline is within +/-15% of value at screening 
7. Regular mucus production due to CF 
8. Ease of sputum expectoration as defined by VAS score equal to or less than 80 mm 
9. Inflammatory markers above upper limit of normal range. 
10. Adequate contraceptive measures. 
11. Able to comply with all protocol requirements 12. Able to use inhalation device.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>To be eligible for inclusion into this trial, each patient must not violate any one of the following exclusion criteria at the time of screening, at the time of assessment or as specifically described below: 
1. Any contraindication to Monoparin( Registered Trademark) considered clinically relevant 
2. Increased bleeding risk 
3. History of heparin-induced thrombocytopaenia 
4. Patients with bleeding diathesis 
5. Evidence of portal hypertension (e.g., hypersplenism or known grade III/IV oesophageal varices) 
6. Clinically significant liver disease 
7. Pregnancy at screening, or lactation 
8. Previous thoracic or scheduled major surgery during trial 
9. Any regular anticoagulant therapy (e.g., warfarin, aspirin) in the two weeks prior to screening 
10. Modification of medication to treat respiratory disease between screening and baseline (Day 1) 
11. Diagnosis or history of aspergilloma 
12. Clinically significant serious disease or organ system disease not currently controlled / stable on present therapy 
13. Planned hospitalisations which could interfere with trial compliance 
14. Unable for any other reason to satisfactorily comply with the protocol (e.g., attendance for trial visits, treatment or assessments)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>26/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>64</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2305</postcode>
    <postcode>4215</postcode>
    <postcode>3052</postcode>
    <postcode>6009</postcode>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vectura Limited (UK)</primarysponsorname>
    <primarysponsoraddress>1 Prospect West
Chippenham
Wiltshire
SN14 6FH</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Vectura Limited (UK)</fundingname>
      <fundingaddress>1 Prospect West
Chippenham
Wiltshire
SN14 6FH</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>ORION Clinical Services (Australia) Pty Ltd</sponsorname>
      <sponsoraddress>141 Osborne Street
South Yarra, VIC 3141</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The clinical trial is to assess the safety and tolerability and to explore the efficacy of orally inhaled heparin in patients with cystic fibrosis (CF). Heparin is expected to provide advantages over currently available treatments for CF in a convenient delivery system.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multi-Centre Research Ethics Committee for Wales</ethicname>
      <ethicaddress>Churchill House
4th Floor 17 Churchill Way
Cardiff CF10 2TW</ethicaddress>
      <ethicapprovaldate>18/03/2008</ethicapprovaldate>
      <hrec>07/MRE09/74</hrec>
      <ethicsubmitdate>21/11/2007</ethicsubmitdate>
      <ethiccountry>United Kingdom</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincents Healthcare Ethics and Medical Research Committee</ethicname>
      <ethicaddress>St Vincents University Hospital
Elm Park
Dublin 4</ethicaddress>
      <ethicapprovaldate>11/11/2008</ethicapprovaldate>
      <hrec>none allocated</hrec>
      <ethicsubmitdate>13/02/2008</ethicsubmitdate>
      <ethiccountry>Ireland</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bioethics Committee University of Lodz</ethicname>
      <ethicaddress>Al. Kosciuszki 4
90-419 Lodz</ethicaddress>
      <ethicapprovaldate>14/07/2009</ethicapprovaldate>
      <hrec>RNN/99/09/KE</hrec>
      <ethicsubmitdate>21/04/2009</ethicsubmitdate>
      <ethiccountry>Poland</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Comitato Etico per la Sperimentazione, Azienda Ospedaliera Universitaria Integrata Verona</ethicname>
      <ethicaddress>Piazzale A. Stefani, 1
Verona, VR 37126</ethicaddress>
      <ethicapprovaldate>7/04/2010</ethicapprovaldate>
      <hrec>17940/CE</hrec>
      <ethicsubmitdate>22/02/2010</ethicsubmitdate>
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>229 Greenhill Road, Dulwich, South Australia 5065</ethicaddress>
      <ethicapprovaldate>20/04/2010</ethicapprovaldate>
      <hrec>C22/10</hrec>
      <ethicsubmitdate>17/03/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hunter New England NSW HREC</ethicname>
      <ethicaddress>New Lambton NSW 2305</ethicaddress>
      <ethicapprovaldate>28/05/2010</ethicapprovaldate>
      <hrec>10/04/21/3.04</hrec>
      <ethicsubmitdate>2/03/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gold Coast Health Service District HREC</ethicname>
      <ethicaddress>Nerang Street SOUTHPORT QLD 4215</ethicaddress>
      <ethicapprovaldate>15/07/2010</ethicapprovaldate>
      <hrec>HREC/10/QGC/55</hrec>
      <ethicsubmitdate>8/04/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Mark Main</name>
      <address>Vectura Limited(UK)
1 Prospect West
Chippenham
Wiltshire
SN14 6FH</address>
      <phone>+ 44 (0) 1249 667 700</phone>
      <fax />
      <email>mark.main@vectura.com</email>
      <country>United Kingdom</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Albert Shen</name>
      <address>ORION Clinical Services (Australia) Pty Ltd
141 Osborne Street
South Yarra, VIC 3141</address>
      <phone>+61 (0) 3 9867 1064</phone>
      <fax>+61 (0) 3 9867 1086</fax>
      <email>albert.shen@orioncro.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mrs Jennifer Piercy</name>
      <address>Vectura Limited (UK)
1 Mere Way
Ruddington 
Nottingham
NG25 0PP</address>
      <phone>+ 44 (0) 115 974 8443</phone>
      <fax />
      <email>jenny.piercy@vectura.com</email>
      <country>United Kingdom</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>